Clinical trials: Neurodegenerative Disease
Diabetes Mellitus, Alzheimer Dementia
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
The purpose of this project is to study brain imaging of a substance called tau, which is found in brains of persons with Alzheimer's disease, using the Tau binder, 18F-THK-5351, for live imaging of tau in the brain.
- Trial name
- TAUPET (NCT03024944)
- Testing
- 18F-THK-5351
- Where
- United States
- Sponsor
- Columbia University
Parkinson Disease
French Parkinson's Disease Cohort - NS-PARK
The aim of NS-PARK cohort are to describe the natural history of Parkinson's disease (PD), and to propose patients stratification models based on PD pathophysiological mechanisms.
- Trial name
- NS-PARK (NCT04888364)
- Where
- France
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Spinal Muscular Atrophy Type I
Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1
GB221 is a gene therapy that delivers a working SMN1 gene to the motor neurons of people with spinal muscular atrophy (SMA) Type 1. This study will evaluate the safety, tolerability and efficacy of GB221 in two groups: 1.
- Trial name
- NCT07070999
- Testing
- GB221
- Where
- Brazil
- Volunteers
- 22 people
- Sponsor
- Gemma Biotherapeutics
Huntington Disease
Longitudinal Endpoint Assessment of Disease Burden in HD
LEAD-HD is intended to collect and analyze self-reported health information from individuals with Huntington Disease (HD) or prodromal HD participating in a 24-month longitudinal natural history study using remote technologies.
- Trial name
- LEAD-HD (NCT06475898)
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Huntington Study Group
Parkinson Disease
Parkinson's Foundation Surveys
Parkinson's Foundation Surveys is an initiative seeking to periodically survey people with Parkinson's disease (PD), their care partners and medical professionals to better understand specific aspects of living with PD.
- Trial name
- NCT05066763
- Testing
- Non-interventional
- Where
- United States
- Volunteers
- 1,000,000 people
- Sponsor
- Parkinson's Foundation
Alzheimer's Disease
Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease
The investigators hypothesize that Nilotinib will be safe in individuals with mild to moderate AD. Specifically, investigators hypothesize that low daily oral doses of Nilotinib will lead to CSF penetration, CNS Abl inhibition…
- Trial name
- AD (NCT02947893)
- Testing
- Nilotinib Capsule(s) Once a Day by Mouth
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Georgetown University
Parkinson Disease
Study on Preliminary Safety and Efficacy of the ARC-IM Therapy to Alleviate Locomotor Deficits in People With Parkinson's Disease
The purpose of this clinical trial is to assess the preliminary safety and efficacy of the ARC-IM spinal cord stimulation therapy in alleviating locomotor deficits in individuals with Parkinson's disease.
- Trial name
- SPARKL (NCT06295614)
- Testing
- ARC-IM System implantation
- Where
- Switzerland
- Volunteers
- 6 people
- Sponsor
- Ecole Polytechnique Fédérale de Lausanne
Parkinson's Disease, Pain
Dopaminergic Loss and Pain in Parkinson's Disease
About 46% of patients suffering from Parkinson's disease present pain disorders. Parkinson disease is characterized by loss of dopaminergic neurons.
- Trial name
- NCT00940914
- Testing
- ioflupane 123I (DATSCAN®)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Toulouse
Parkinson's Disease, Movement Disorders
Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's Disease Patients
The goal of this clinical trial is to explore the effects of cerebellar nuclei TIS stimulation on improving tremor and gait disorders in PD patients.
- Trial name
- NCT07384442
- Testing
- Real Temporal Interference Stimulation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- YangPan
Multiple Sclerosis, Exercise Intervention
Regular Exercise Improves Physical Capacity and Promotes Neurotrophins in Patients With Multiple Sclerosis
ABSTRACT Objective: The investigators aimed to determine the effect of regular exercise on aerobic capacity, strength values, and plasma levels of nerve growth factor (NGF) and Neurotrophin-3 (NT-3) in patients with multiple…
- Conditions
- Multiple Sclerosis, Exercise Intervention, Neuro-Degenerative Disease
- Trial name
- NCT04944251
- Testing
- Regular Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 43 people
- Sponsor
- Ege University
Parkinson Disease
Treatment of Balance Disorders in Parkinson's Patients Using SpotOn Balance Glasses
An open-label study to evaluate the effect of SpotOn balance glasses in non-demented Parkinson's patients with balance disorders.
- Trial name
- NCT03942172
- Testing
- SpotOn balance glasses
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- SpotOn Therapeutics Ltd.
Parkinson's Disease
Crossover Versus Stabilometric Platform in Parkinson's Disease
The aims of this study is to assess the efficacy of the crossover on balance in Parkinsonian patients and compare this results with the results of a control group of patients treated with a stabilometric platform.
- Trial name
- PDvsCOPD (NCT02098577)
- Testing
- Crossover, Stabilometric Platform
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Ospedale Generale Di Zona Moriggia-Pelascini
Multiple System Atrophy
Cognitive and Behavioral Dysexecutive Syndrome in Multiple System Atrophy
The main objective of the study is to compare the score to the Behavioral Dysexecutive Syndrome Inventory (BDSI) between Parkinsonian Multiple system Atrophy MSA-P patients and cerebellar Multiple System Atrophy (MSA-C) patients…
- Trial name
- CogAMS (NCT02185677)
- Testing
- Clinical evaluation, neuropsychological battery test, MRI
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Bordeaux
Dystonia, Parkinson Disease
DYSCAR: Characterization of Dystonia
Dystonia is a rare disease leading to a severe handicap. It can be of primary or secondary origin. It is characterized by sustained muscle contractions, frequently causing twisting and repetitive movements or abnormal postures.
- Trial name
- NCT00361465
- Testing
- EMG and Kinematics recording
- Where
- France
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Study the Role of SHMT1 Polymorphism in Parkinson Disease
SHMT1 Polymorphism in Parkinson's Disease,
Parkinson Disease (PD) is the most common movement disorder and represents the second most common degenerative disease of the central nervous system . SHMT has been shown to be associated with various diseases.
- Trial name
- NCT04706065
- Testing
- SHMT1 polymorphism
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assiut University
Alzheimer Disease, Alzheimer' Disease
A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease
The purpose of this study is to investigate the safety and efficacy of BEY2153 in patients with early Alzheimer's Disease. Subjects who meet the inclusion and exclusion criteria will be randomized 1:1:1 to one of three treatment…
- Trial name
- NCT06885567
- Testing
- BEY2153
- Where
- 3 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- BeyondBio Inc.
Dementia With Lewy Bodies (DLB)
A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
The purpose of this clinical study is to evaluate the safety and tolerability (side effects) and pharmacokinetics (drug levels in the body) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.
- Trial name
- NCT06815965
- Testing
- neflamapimod
- Where
- 2 sites in France
- Volunteers
- 26 people
- Sponsor
- EIP Pharma Inc
Parkinson's Disease
Efficacy of Ethnodyne Visio in Parkinson's Disease
ETHNODYNE VISIO is a food supplement composed of an innovative plant-based active ingredient acting alongside vitamin B2. It is proposed in patients with visual problems.
- Trial name
- ETHNOPARK (NCT02815800)
- Testing
- ETHNODYNE VISIO
- Where
- France
- Volunteers
- 24 people
- Sponsor
- University Hospital, Strasbourg, France
Alzheimers Disease
A Post Authorization Registry Study of Participants Treated With LEQEMBI
To describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities-edema (ARIA-E), ARIA microhemorrhage and hemosiderin deposit (ARIA-H), and intracerebral hemorrhage greater than 1 cm…
- Trial name
- NCT07762092
- Testing
- No Intervention
- Where
- 17 sites in Canada
- Volunteers
- 400 people
- Sponsor
- Eisai Limited
Alzheimer Disease, Early Onset, Alzheimer Disease
Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks
This study attempts to identify two types of AD by using clinical and cognitive tasks and brain imaging. The subtypes of AD are separated into a "typical" group (memory loss) and a "variant" group (language, visuospatial, and…
- Conditions
- Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Disease, Late Onset, Dementia, Alzheimer Type
- Trial name
- EOAD-Subtype (NCT03153371)
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles